Oncodesign Precision Medicine receives a grant for the development of the OPM-201

Oncodesign Precision Medicine (OPM) announced it has received a $6.92 million grant from the Michael J. Fox Foundation. This funding will support the development of its LRRK2 inhibitor, OPM-201, for the treatment of Parkinson's disease. Specifically, it will enable the company to produce the drug for the Phase 1b and Phase 2 clinical trials scheduled for 2027.

This advancement is part of the LRRK2 Investigative Therapeutics Exchange program, demonstrating the interest in the molecule. OPM plans to conduct these clinical trials in partnership with international experts.

The promising results of previous studies, conducted on healthy volunteers, demonstrated good target engagement and an acceptable safety profile. Furthermore, preclinical studies have confirmed the selectivity of OPM-201, reinforcing its position as a potential candidate for modifying the course of Parkinson's disease.